Anteris Unveils Positive DurAVR Transcatheter Heart Valve Results in Small-Annulus Cohort

Anteris Technologies has released 30-day clinical results for its DurAVR transcatheter heart valve, reporting strong safety and performance outcomes in 100 severe aortic stenosis patients with small aortic annuli. The data show a mean effective orifice area of 2.2 square centimeters and a single-digit mean pressure gradient of 8.2 mmHg. The company is progressing its global PARADIGM randomized trial, comparing DurAVR against marketed TAVR systems.